Freeze variability, not progress: strengthen your cell therapy supply chain from the start

What It Covers

Dominic Clark, VP of Technical Operations at IntegraCell (Cryoport Systems), explains why cell therapy programs default to fresh leukapheresis workflows, how late-stage cryopreservation adoption creates costly regulatory and operational problems, and how IntegraCell's automated closed process standardizes starting material handling from early development through global commercialization.

Key Questions Answered

• •Fresh vs. Frozen Starting Material: Fresh workflows persist due to inherited academic processes, not data superiority. Once programs enter the clinic with fresh workflows, those decisions become locked in — making later pivots costly and regulatory-intensive. Teams should evaluate cryopreservation at Phase I design, not during scale-up, to avoid forced process changes under high regulatory scrutiny.
• •Automated Closed Process (ACP) Design: IntegraCell's ACP uses a Fresenius Kabi Q system to automate leukapheresis washing, concentration, cryoprotectant formulation, and bag filling in a closed system. This removes operator-dependent manual handling steps, reducing two primary variability sources — time and people — while producing cell viability and recovery comparable to fresh starting material.
• •Cryopreservation as Regulatory Strategy: Validated cryopreservation strengthens regulatory submissions by demonstrating reproducibility and process control. Data from an IntegraCell-CellAd collaboration showed the ACP preserves key T cell subsets, activation profiles, and phenotypic identity at levels functionally equivalent to fresh material, providing documented evidence regulators can assess for consistency across manufacturing batches.
• •Multi-Site Standardization Gap: A single validated cryopreservation process deployed across multiple collection sites eliminates site-to-site variation. IntegraCell addresses this by offering the same ACP protocol, quality system, and SOPs across all global locations — including a Paris facility opened in 2024 and a Southern California site opening in 2025 — rather than allowing each site to run independent manual variants.
• •Proactive Dual-Track Planning: Programs committed to fresh workflows should still develop and validate a cryopreserved starting material option in parallel. Maintaining a frozen backup decouples manufacturing from clinical scheduling, enables inventory management, and provides operational flexibility if logistics, patient geography, or scale demands shift — without requiring a disruptive mid-program process change under regulatory review.